financetom
Business
financetom
/
Business
/
NCino Fiscal Q2 Non-GAAP Earnings, Revenue Rise; Q3 Outlook Set; Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NCino Fiscal Q2 Non-GAAP Earnings, Revenue Rise; Q3 Outlook Set; Shares Fall After Hours
Aug 28, 2024 1:19 AM

04:29 PM EDT, 08/27/2024 (MT Newswires) -- NCino ( NCNO ) reported fiscal Q2 non-GAAP earnings late Tuesday of $0.14 per diluted share, up from $0.09 a year earlier.

Analysts polled by Capital IQ expected $0.13.

Revenue in the quarter ended July 31 rose to $132.4 million from $117.2 million a year earlier.

Analysts surveyed by Capital IQ expected $131.1 million.

The company expects Q3 non-GAAP EPS of $0.15 to $0.16 on revenue of $136 million to $138 million.

Analysts polled by Capital IQ expect EPS of $0.16 on revenue of $138.7 million.

For fiscal 2025, the company raised non-GAAP EPS guidance to $0.66 to $0.69 from $0.65 to $0.68 and reiterated its revenue outlook of $538.5 million to $544.5 million.

Analysts surveyed by Capital IQ expect EPS of $0.67 on revenue of $541.7 million.

The shares of nCino fell 8.8% in after-hours activity.

Price: 31.50, Change: -3.03, Percent Change: -8.77

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nouveau Monde Graphite 2024 Net Loss Widens
Nouveau Monde Graphite 2024 Net Loss Widens
Mar 31, 2025
08:58 AM EDT, 03/31/2025 (MT Newswires) -- Nouveau Monde Graphite ( NMG ) was 2.7% higher at last look Monday in NYSE pre-market trading after reporting a higher net loss for 2024, but a narrower loss per share. The company reported a 2024 net and comprehensive loss of $73.3 million, or $0.71 per share, compared to a 2023 net and...
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment
Mar 31, 2025
08:59 AM EDT, 03/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting. The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B....
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Mar 31, 2025
Vaxcyte Inc. ( PCVX ) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc’s Prevnar 20 (PCV20) in healthy infants. The company has selected the VAX-24 Mid-dose as the basis for advancing an optimized...
Slowing German Inflation Paves The Way for Further ECB Rate Cuts, Says ING
Slowing German Inflation Paves The Way for Further ECB Rate Cuts, Says ING
Mar 31, 2025
08:55 AM EDT, 03/31/2025 (MT Newswires) -- Monday's flash estimate of German inflation for March brought further relief for the European Central Bank as headline inflation came in at 2.2% year-on-year, down from 2.3% in February, said ING. Core inflation came down to 2.5% year over year from 2.6%. The European inflation measure dropped to 2.3% year over year from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved